- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/22 - Anxiolytics
Patent holdings for IPC class A61P 25/22
Total number of patents in this class: 2515
10-year publication summary
|
44
|
62
|
120
|
164
|
149
|
170
|
195
|
189
|
198
|
167
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2717 |
45 |
| Taisho Pharmaceutical Co., Ltd. | 860 |
45 |
| F. Hoffmann-La Roche AG | 7933 |
36 |
| AstraZeneca AB | 2858 |
35 |
| Hoffmann-La Roche Inc. | 3533 |
32 |
| Société des Produits Nestlé S.A. | 9886 |
26 |
| H. Lundbeck A/S | 1237 |
26 |
| Intra-Cellular Therapies, Inc. | 420 |
23 |
| Sage Therapeutics, Inc. | 375 |
23 |
| Daiichi Sankyo Company, Limited | 1877 |
18 |
| Nippon Chemiphar Co., Ltd. | 232 |
18 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
17 |
| Janssen Pharmaceutica N.V. | 3351 |
16 |
| The Trustees of Columbia University in the City of New York | 3606 |
16 |
| Bionomics Limited | 89 |
16 |
| Compass Pathfinder Limited | 110 |
16 |
| Glaxo Group Limited | 4117 |
14 |
| Les Laboratoires Servier | 523 |
14 |
| The Regents of the University of California | 20289 |
13 |
| Raqualia Pharma Inc. | 122 |
13 |
| Other owners | 2053 |